Stocktoria
Eton Pharmaceuticals, Inc. ETON
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-11-09
Eton Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.0M |
| R&D expense | $7.8M | $3.3M | $3.3M | $4.0M | $6.2M |
| Operating income | -$844,000 | -$2.6M | -$1.2M | -$8.3M | -$1.5M |
| Interest expense | — | — | $1.1M | $955,000 | $1.0M |
| Income tax | $43,000 | $15,000 | $247,000 | $0 | $0 |
| Net income | -$4.6M | -$3.8M | -$936,000 | -$9.0M | -$2.0M |
| Operating cash flow | $10.5M | $969,000 | $6.8M | $4.8M | -$4.7M |
| Free cash flow | $10.2M | $943,000 | $6.8M | $4.8M | -$4.7M |
| Cash & equivalents | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M |
| Inventory | $15.4M | $15.2M | $911,000 | $557,000 | $550,000 |
| Total assets | $92.1M | $76.1M | $31.7M | $25.0M | $27.5M |
| Total liabilities | $66.0M | $51.7M | $16.3M | $12.0M | $9.8M |
| Shareholders' equity | $26.2M | $24.4M | $15.5M | $13.1M | $17.6M |
Source: SEC EDGAR filings · CIK 0001710340 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.